12.07.2015 Views

NSERC grants at Laurentian University Subventions du CRSNG `a l ...

NSERC grants at Laurentian University Subventions du CRSNG `a l ...

NSERC grants at Laurentian University Subventions du CRSNG `a l ...

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

134the cell has multiple mechanisms to control ERK activity. A gre<strong>at</strong> deal ofresearch on drugs th<strong>at</strong> can block the ERK p<strong>at</strong>hway has been carried out,and a number of compounds th<strong>at</strong> block the p<strong>at</strong>hway upstream of ERK havebeen identified and are in common use. The MEK inhibitors in particularare often used to demonstr<strong>at</strong>e the involvement of ERK in cellular regul<strong>at</strong>ion.However, there are no drugs th<strong>at</strong> can directly inhibit ERK. Given th<strong>at</strong> ERKcan be activ<strong>at</strong>ed by mechanisms th<strong>at</strong> bypass the classical p<strong>at</strong>hway, inhibitionof MEK is not always sufficient to identify ERK regul<strong>at</strong>ed processes. Wehave recently identified a drug, SU1498, which directly inhibits ERK kinaseactivity. The studies proposed here are designed to understand how SUl498works as an ERK inhibitor and to examine the effects of SUl498 in severaldifferent cell systems. SUl498 will provide the basis for the development ofa new class of ERK inhibitor compounds with gre<strong>at</strong>er potency and selectivity.These drugs will permit the study of ERK regul<strong>at</strong>ed processes in bothnormal and dysfunctional cells.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!